Use of SBRT in Treating Pancreatic Cancer

Video

This video highlights the evolution of stereotactic body radiation therapy in the treatment of pancreatic cancer.

In this video, Sarah E. Hoffe, MD, of the Moffitt Cancer Center in Tampa, Florida, discusses the evolution of stereotactic body radiation therapy (SBRT) for the treatment of pancreatic cancer.

Hoffe also highlights a recent study published in Lancet Oncology using a genomic-adjusted radiation dose (GARD) in patients with various malignancies, a method that could individualize radiotherapy treatment.

Recent Videos
Only a few groups of patients get screened for pancreatic cancer, those with a genetic risk or pancreatic cysts among them, which can increase lethality for unidentified populations.
The development of RAS-directed vaccines may help decrease the likelihood of disease recurrence in patients undergoing treatment for pancreatic cancer.
Related Content
Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer

Dostarlimab-gxly Granted Breakthrough Therapy Designation for Rectal Cancer

Tim Cortese
December 16th 2024
Article

Dostarlimab achieved a 100% clinical complete response rate in patients with dMMR/MSI-H advanced rectal cancer, a phase 2 study found.

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

Kelley A. Rone, DNP, RN, AGNP-c
December 2nd 2024
Podcast

A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

Advancing Pancreatic Cyst Surveillance and Care Pathways Via AI Software

Russ Conroy
December 11th 2024
Article

An artificial intelligence model may help move patients into treatment pathways for pancreatic cancer quicker, says Russell C. Langan, MD, FACS, FSSO.

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

Advancing Research and Targeting Genomic Alterations in Pancreatic Cancer

Tanios S. Bekaii-Saab, MD, FACP
November 25th 2024
Podcast

Tanios S. Bekaii-Saab, MD, provides an overview of current therapy options and ongoing initiatives involving targetable alterations in those with pancreatic cancer.

FDA Approves Zenocutuzumab in NSCLC/Pancreatic Cancer

FDA Approves Zenocutuzumab in NSCLC/Pancreatic Cancer

Ariana Pelosci
December 4th 2024
Article

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

TTFields/Chemotherapy Improves Survival in Advanced Pancreatic Cancer

TTFields/Chemotherapy Improves Survival in Advanced Pancreatic Cancer

Tim Cortese
Published: December 3rd 2024 | Updated: December 3rd 2024
Article

Tumor treating fields with chemotherapy improved overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma.